Suppr超能文献

治疗前中性粒细胞/淋巴细胞比值作为传统型软骨肉瘤预后因素的影响

Impact of the Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor in Conventional Chondrosarcoma.

作者信息

Clara-Altamirano Miguel Angel, de Los Santos-Quintanilla Amelia Rebeca, Luna-Ortiz Kuauhyama, Alvarez-Cano Alethia, Velazquez-Rodriguez Stephanie, Lizcano-Suárez Anderson Ruben, García-Ortega Dorian Yarih

机构信息

Skin, Soft Tissue, and Bone Tumors Department, National Cancer Institute of Mexico, Center for Research in Health Sciences, Faculty of Health Sciences, North Anahuac University, Anahuac University Avenue #46, Lomas Anahuac, 52786 Naucalpan de Juárez, Mexico.

Health Sciences Research Committee, Faculty of Health Sciences, North Anahuac University, Anahuac University, Naucalpan de Juárez, Mexico.

出版信息

Indian J Surg Oncol. 2025 Feb;16(1):356-363. doi: 10.1007/s13193-024-02100-y. Epub 2024 Sep 23.

Abstract

Conventional chondrosarcoma (CCS) is the most frequent histological subtype of chondrosarcoma (CS). Currently, researchers have paid much attention to the neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker of various diseases. Although a specific value has not yet been established, it is widely recognized as a reflection of the immune system's balance. Studies have shown that NLR has a strong correlation with disease outcomes and has been found to be independently related to the mortality rate caused by some types of cancer. This research aimed to analyze the prognostic significance of preoperative NLR in a cohort of patients with CCS at a reference sarcoma center. We conducted a retrospective cohort study of 58 patients with a diagnosis of CCS non-metastatic to evaluate the association between preoperative NLR and overall survival (OS). We used Kaplan-Meier curves and Cox proportional models for our analysis. The study found that CCS patients with high NLR had a significantly increased risk of poor prognosis in OS. We found no association between the NLR and the DFS. Of the 58 patients included in the retrospective cohort, 51.7% were male, with a mean age at diagnosis of 42 years and a standard deviation of ± 13.4. The axial skeleton was the most common site of CCS in 56.9% of the patients ( = 33). The median follow-up time was 39.4 months, ranging from 6 to 66 months. High NLR was significantly associated with lower OS. New prospective studies are needed to better characterize the role of serum markers in the prognosis of these patients and to better plan future treatment.

摘要

传统型软骨肉瘤(CCS)是软骨肉瘤(CS)最常见的组织学亚型。目前,研究人员已将中性粒细胞与淋巴细胞比值(NLR)作为多种疾病的预后生物标志物予以高度关注。尽管尚未确定具体数值,但它被广泛认为是免疫系统平衡的一种反映。研究表明,NLR与疾病预后密切相关,且已发现其与某些类型癌症导致的死亡率独立相关。本研究旨在分析在一家参考肉瘤中心的一组CCS患者中术前NLR的预后意义。我们对58例诊断为非转移性CCS的患者进行了回顾性队列研究,以评估术前NLR与总生存期(OS)之间的关联。我们使用Kaplan-Meier曲线和Cox比例模型进行分析。研究发现,NLR高的CCS患者OS预后不良风险显著增加。我们发现NLR与无病生存期(DFS)之间无关联。在纳入回顾性队列的58例患者中,51.7%为男性,诊断时的平均年龄为42岁,标准差为±13.4。56.9%的患者(n = 33)中,轴骨是CCS最常见的部位。中位随访时间为39.4个月,范围为6至66个月。高NLR与较低的OS显著相关。需要新的前瞻性研究来更好地描述血清标志物在这些患者预后中的作用,并更好地规划未来治疗。

相似文献

1
Impact of the Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor in Conventional Chondrosarcoma.
Indian J Surg Oncol. 2025 Feb;16(1):356-363. doi: 10.1007/s13193-024-02100-y. Epub 2024 Sep 23.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
6
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
9
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
10
Single-incision sling operations for urinary incontinence in women.
Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD008709. doi: 10.1002/14651858.CD008709.pub3.

本文引用的文献

2
Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma.
Cells. 2024 Jun 4;13(11):977. doi: 10.3390/cells13110977.
3
Neutrophil-to-Lymphocyte ratio as a prognostic biomarker in extremities undifferentiated pleomorphic sarcoma.
Surg Oncol. 2022 Jun;42:101746. doi: 10.1016/j.suronc.2022.101746. Epub 2022 Mar 29.
4
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Int J Mol Sci. 2022 Jan 20;23(3):1096. doi: 10.3390/ijms23031096.
5
Chondrosarcoma-from Molecular Pathology to Novel Therapies.
Cancers (Basel). 2021 May 14;13(10):2390. doi: 10.3390/cancers13102390.
6
Chondrosarcoma.
J Am Acad Orthop Surg. 2021 Jul 1;29(13):553-562. doi: 10.5435/JAAOS-D-20-01188.
7
Association of Preoperative Neutrophil/Lymphocyte Ratio with Clinical Outcomes in Dedifferentiated Chondrosarcoma Patients.
Cancer Manag Res. 2020 Aug 3;12:6719-6726. doi: 10.2147/CMAR.S266671. eCollection 2020.
9
Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer.
Sci Rep. 2019 Dec 23;9(1):19673. doi: 10.1038/s41598-019-56218-z.
10
Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis.
J Orthop Res. 2020 Feb;38(2):311-319. doi: 10.1002/jor.24463. Epub 2019 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验